Roche scores—again—in hemophilia drug patent case against Takeda

In a patent case centered on two rival hemophilia medicines, Roche's Genentech unit has scored its second straight win.

After a U.S. district court last year ruled in favor of Roche and invalidated a patent held by Takeda's Baxalta unit, the U.S. Court of Appeals for the Federal Circuit reaffirmed the ruling.